Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ESElizabeth StengerSBStephanie Bo‐SubaitHSHélène Schoemans

Discussion

Loading...

Member takes

Overview

Analysis reveals long-term survival and late effects in patients post-hematopoietic cell transplantation for sickle cell disease, indicating improved outcomes with matched donors.

Key Points

  • Average overall survival rates at 7 years post-HCT were approximately 90%, showing promising outcomes for sickle cell disease patients.
  • Cumulative incidence of late effects included liver toxicity at 10% and diabetes at 6%, indicating risks associated with long-term HCT.
  • Observational analysis evaluated risk factors for late effects, using multivariable Cox regression to determine influences on survival and complications.
  • Supportive findings highlight the need for improved graft-versus-host disease prevention strategies to enhance post-HCT outcomes.

Cite This Study

Stenger et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d764https://doi.org/10.1182/blood-2025-1051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Haploidentical hematopoietic stem cell transplantation in adults with severe sickle cell disease: Long-term outcomes using a modified conditioning regimen with peripheral blood stem cells.2025 · 1 citations
  2. 2Encouraging Outcomes of Hematopoeitic Stem Cell Transplantation in Pediatric Sickle Cell Disease- A Decade-Long Experience from the Developing World2025
  3. 3The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.2025 · 1 citations
  4. 4Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025
  5. 5Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025